Pantoprazole withdrawal symptoms

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Pantoprazole Withdrawal Symptoms: Insights from Recent Research

Introduction to Pantoprazole and Its Use

Pantoprazole is a proton pump inhibitor (PPI) commonly prescribed for the treatment of gastroesophageal reflux disease (GERD) and other acid-related disorders. While effective in managing symptoms, concerns have been raised about potential withdrawal symptoms following discontinuation.

GERD Symptom Management in Infants

A study focusing on infants aged 1 to 11 months with symptomatic GERD evaluated the efficacy and safety of pantoprazole. The research involved an initial open-label phase followed by a double-blind, placebo-controlled withdrawal phase. Results indicated that pantoprazole significantly improved GERD symptom scores during the open-label phase. However, during the withdrawal phase, there were no significant differences in withdrawal rates due to lack of efficacy between the pantoprazole and placebo groups. This suggests that pantoprazole was well tolerated, and withdrawal did not lead to a significant resurgence of GERD symptoms in infants .

Dyspeptic Symptoms Post-Discontinuation in Adults

Another study investigated the development of dyspeptic symptoms after discontinuing pantoprazole in healthy, Helicobacter pylori-negative adults. Participants were randomized to receive either pantoprazole or a placebo for 28 days. Following discontinuation, a significant number of individuals in the pantoprazole group developed dyspeptic symptoms compared to the placebo group. Specifically, 44% of the pantoprazole group experienced dyspepsia versus 9% in the placebo group during the first week post-treatment. These symptoms were correlated with elevated gastrin levels, suggesting that acid rebound hypersecretion might be responsible for the observed dyspeptic symptoms .

Conclusion

The research indicates that while pantoprazole is effective in managing GERD symptoms, discontinuation can lead to withdrawal symptoms, particularly dyspepsia, due to acid rebound hypersecretion. This effect is more pronounced in adults than in infants, highlighting the need for careful management when discontinuing pantoprazole therapy.

Sources and full results

Most relevant research papers on this topic

Efficacy and Safety of Pantoprazole Delayed-release Granules for Oral Suspension in a Placebo-controlled Treatment-withdrawal Study in Infants 1–11 Months Old With Symptomatic GERD

Pantoprazole significantly improved GERD symptom scores in infants and was well-tolerated, but during the randomized, double-blind, placebo-controlled treatment phase, no significant differences were found in withdrawal rates due to lack of efficacy.

RCTVery Rigorous Journal

2010·

68citations

·H. Winter et al.

Dyspeptic Symptom Development After Discontinuation of a Proton Pump Inhibitor: A Double-Blind Placebo-Controlled Trial

Discontinuing pantoprazole treatment can induce dyspeptic symptoms in previously asymptomatic healthy H. pylori-negative subjects, likely due to acid rebound hypersecretion.

RCTRigorous JournalHighly Cited

2010·

151citations

·A. Niklasson et al.

Protective Effects of Vitamin E on Pantoprazole Adverse Effects

Vitamin E can reduce the adverse effects of pantoprazole by increasing antioxidant enzymes and reducing liver fatty changes and renal tubular epithelium degeneration.

RCT

2019·

0citations

·G. Shams et al.

The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients.

Pantoprazole does not influence enteric-coated mycophenolate sodium pharmacokinetics in heart or lung transplant recipients, as it does for mycophenolate mofetil.

Non-RCT

2011·

32citations

·S. Kofler et al.

Pantoprazole-induced acute interstitial nephritis.

Pantoprazole can cause acute interstitial nephritis, requiring renal replacement therapy, and vigilance is needed when prescribing proton-pump inhibitors like pantoprazole.

Case Report

2004·

11citations

·I. Moore et al.

Pantoprazole/unspecified antibacterials

Drug fever can occur during treatment with pantoprazole and unspecified antibacterials, and is often resolved when these medications are discontinued.

Case Report

2021·

0citations

Efficacy of pantoprazole compared with omeprazole in prevention of relapse of reflux esophagitis: Double-blind, randomized multicenter trial

Both pantoprazole 20-40 mg and omeprazole 20 mg are equally effective and safe for preventing recurrence of reflux esophagitis.

RCTLarge Human Trial

2000·

2citations

·K. Lauritsen et al.

Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease – PAN-STAR

Pantoprazole 40 mg once daily is an effective and well-tolerated treatment for providing symptom relief and improving quality of life in patients with gastroesophageal reflux disease.

Meta-Analysis

2018·

10citations

·Andrzej Dabrowski et al.

Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease – PAN-STAR

Pantoprazole 40 mg once daily effectively provides symptom relief and improves quality of life for most patients with gastroesophageal reflux disease (GERD).

Meta-Analysis

2018·

10citations

·A. Dabrowski et al.

Multicenter, Randomized, Double-Blind Study Comparing 10, 20 and 40 mg Pantoprazole in Children (5-11 Years) With Symptomatic Gastroesophageal Reflux Disease

Pantoprazole (20 and 40 mg) effectively reduces gastroesophageal reflux disease symptoms in children, with both doses significantly improving symptoms as early as 1 week.

RCT

2006·

69citations

·V. Tolia et al.

Try another search

global warming diagram

over the counter medicine to lower heart rate

acceleration of climate change

clonidine 0.1 mg used for

is gabapentin good for arthritis

is acid reflux and gerd the same